Gregory Moore
FortiveAbout Gregory J. Moore
Independent director appointed February 26, 2025. Senior advisor to Gates Ventures; formerly Corporate Vice President, Microsoft Health & Life Sciences (2019–2023), and VP/Founder of Google Cloud Healthcare & Life Sciences (2016–2019). Board-certified in Diagnostic Radiology, Neuroradiology, and Clinical Informatics; PhD in Radiological Sciences (MIT) and MD (Wayne State). Currently a director at DaVita, Inc. (since 2021). Appointed via a third‑party search firm engaged by the Nominating & Governance Committee; Board affirmed independence under NYSE standards.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Microsoft Corporation | Corporate Vice President, Health & Life Sciences | 2019–2023 | Led digital health initiatives; senior technology leadership |
| Google Inc. | VP & Founder, Google Cloud Healthcare & Life Sciences | 2016–2019 | Built cloud healthcare practice; advanced AI/ML strategies |
| Geisinger Health System | Chief Emerging Technology & Informatics Officer | Not disclosed | Clinical informatics and emerging tech leadership |
| Stanford University | Associate Fellow, Center for AI in Medicine & Imaging | Current | AI in medicine thought leadership |
External Roles
| Organization | Role | Tenure | Committees/Role Notes |
|---|---|---|---|
| DaVita, Inc. | Director | Since 2021 | US-listed public company board |
| Olink Holding AB | Director | Prior service (dates not disclosed) | Not disclosed |
| Hill-Rom Holdings, Inc. | Director | Prior service (dates not disclosed) | Not disclosed |
Board Governance
- Independence: Board determined Dr. Moore is independent under NYSE standards at appointment; proxy affirms independence among nine of ten directors including Dr. Moore.
- Committee assignments: Member, Compensation Committee; Member, Nominating & Governance Committee. Not on Audit or Finance.
- Attendance: In 2024, the Board met seven times (plus two unanimous written consents); all directors met at least 75% attendance. Note: Dr. Moore joined in 2025; 2024 attendance context applies to overall board.
- Appointment process: Recommended by a third‑party search firm engaged by the Nominating & Governance Committee.
- Indemnification: Entered standard indemnification agreement (form previously filed).
- Compensation Committee remit includes director compensation policy oversight, clawback policy oversight, stock ownership compliance, and engagement on executive pay.
Fixed Compensation
| Component | Amount | Terms |
|---|---|---|
| Annual Director Retainer (cash or RSUs per election) | $105,000 | Payable in cash quarterly or in RSUs under Deferred Compensation Plan (settlement deferred per election). RSUs vest at earlier of 1-year or immediately prior to next annual meeting. |
| Compensation Committee Member Retainer | $10,000 | Payable in cash or RSUs per election. |
| Nominating & Governance Committee Member Retainer | $10,000 | Payable in cash or RSUs per election. |
| Meeting Fees | Not applicable | Not disclosed; no per‑meeting fees described. |
| Chair/Other Committee Fees | Not applicable | Dr. Moore is not a chair. |
- Deferred Compensation Plan elections: Directors may elect cash, RSUs, or a mix (increments of 1%); RSUs settlement deferred to death or selected post‑retirement date (7 months, 1/3/5 years).
Performance Compensation
| Equity Component | Target Value | Mix | Vesting | Notes |
|---|---|---|---|---|
| Annual Equity Award | $200,000 | 75% RSUs / 25% Options | RSUs: earlier of 1-year or immediately prior to next annual meeting; Options: fully vested at grant | Options valued via Black‑Scholes; RSUs valued at grant-date price. |
| Performance Conditions | None disclosed for non‑employee directors | — | — | No revenue/EBITDA/TSR metrics disclosed for director equity. |
The Compensation Committee reviews director pay annually with Pearl Meyer benchmarking.
Other Directorships & Interlocks
| Company | Industry | Relationship to FTV | Interlock/Conflict Notes |
|---|---|---|---|
| DaVita, Inc. | Healthcare services (dialysis) | Potential sector adjacency to Fortive’s Advanced Healthcare Solutions; no direct transaction disclosures | Company states no transactions involving Dr. Moore requiring Item 404(a) disclosure. |
| Olink Holding AB | Proteomics | Prior board service | Not disclosed. |
| Hill‑Rom Holdings, Inc. | Medical devices | Prior board service | Not disclosed. |
- Related‑party transactions: None requiring disclosure under Item 404(a) in connection with Dr. Moore’s appointment.
Expertise & Qualifications
- Medical and informatics credentials: Board‑certified in Diagnostic Radiology, Neuroradiology, Clinical Informatics; PhD (MIT), MD (Wayne State).
- Technology leadership: Senior roles at Microsoft and Google Cloud in digital health/AI; AI research affiliation at Stanford.
- Board skills matrix mentions technology management, cybersecurity, sustainability, and public company experience across nominees; Dr. Moore included among nominees.
Equity Ownership
| Holder | Shares Beneficially Owned (as of April 7, 2025) | % of Class |
|---|---|---|
| Gregory J. Moore | — | * (less than 1%) |
- Ownership policy: Non‑management directors must beneficially own shares equal to at least 5× annual retainer within five years of initial election/appointment; beneficial ownership includes time‑based RSUs but excludes unexercised options. Hedging and pledging of company stock are prohibited.
- Compliance timing: Based on appointment on February 26, 2025, guideline deadline is five years from appointment (February 26, 2030).
Governance Assessment
-
Strengths
- Independent director with deep AI/digital health expertise and clinical credentials—aligned with Fortive’s stated focus on technology enablers and healthcare solutions.
- Immediate placement on Compensation and Nominating & Governance Committees enhances oversight of pay, human capital, and board refreshment; committee members are independent per NYSE rules.
- Director compensation structure emphasizes equity (annual $200k with RSUs/options) and optional deferral into RSUs, supporting longer‑term alignment; hedging/pledging prohibited.
-
Watch items / potential red flags
- Low current beneficial ownership (“—” as of April 7, 2025); however, five‑year 5× retainer guideline provides time to comply.
- External board at DaVita introduces sector adjacency to Fortive’s healthcare businesses; the company discloses no related‑party transactions involving Dr. Moore. Monitor for future interlocks or business dealings.
-
Engagement & Attendance
- Board met seven times in 2024 with all directors ≥75% attendance; as a 2025 appointee, Dr. Moore’s attendance will be evaluated prospectively.
-
Process Integrity
- Appointment via a third‑party search firm and formal independence determination signal strong refreshment and governance rigor.